Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 24(7)2023 Apr 03.
Article in English | MEDLINE | ID: mdl-37047638

ABSTRACT

Major depression is one of the most prevalent mental disorders, causing significant human suffering and socioeconomic loss. Since conventional antidepressants are not sufficiently effective, there is an urgent need to develop new antidepressant medications. Despite marked advances in the neurobiology of depression, the etiology and pathophysiology of this disease remain poorly understood. Classical and newer hypotheses of depression suggest that an imbalance of brain monoamines, dysregulation of the hypothalamic-pituitary-adrenal axis (HPAA) and immune system, or impaired hippocampal neurogenesis and neurotrophic factors pathways are cause of depression. It is assumed that conventional antidepressants improve these closely related disturbances. The purpose of this review was to discuss the possibility of affecting these disturbances by targeting the melanocortin system, which includes adrenocorticotropic hormone-activated receptors and their peptide ligands (melanocortins). The melanocortin system is involved in the regulation of various processes in the brain and periphery. Melanocortins, including peripherally administered non-corticotropic agonists, regulate HPAA activity, exhibit anti-inflammatory effects, stimulate the levels of neurotrophic factors, and enhance hippocampal neurogenesis and neurotransmission. Therefore, endogenous melanocortins and their analogs are able to complexly affect the functioning of those body's systems that are closely related to depression and the effects of antidepressants, thereby demonstrating a promising antidepressant potential.


Subject(s)
Depressive Disorder, Major , Melanocortins , Humans , Melanocortins/pharmacology , Hypothalamo-Hypophyseal System , Pituitary-Adrenal System , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Receptors, Corticotropin , Nerve Growth Factors , Depressive Disorder, Major/drug therapy
2.
Int J Mol Sci ; 24(5)2023 Mar 02.
Article in English | MEDLINE | ID: mdl-36902300

ABSTRACT

The production and transplantation of functionally active human neurons is a promising approach to cell therapy. Biocompatible and biodegradable matrices that effectively promote the growth and directed differentiation of neural precursor cells (NPCs) into the desired neuronal types are very important. The aim of this study was to evaluate the suitability of novel composite coatings (CCs) containing recombinant spidroins (RSs) rS1/9 and rS2/12 in combination with recombinant fused proteins (FP) carrying bioactive motifs (BAP) of the extracellular matrix (ECM) proteins for the growth of NPCs derived from human induced pluripotent stem cells (iPSC) and their differentiation into neurons. NPCs were produced by the directed differentiation of human iPSCs. The growth and differentiation of NPCs cultured on different CC variants were compared with a Matrigel (MG) coating using qPCR analysis, immunocytochemical staining, and ELISA. An investigation revealed that the use of CCs consisting of a mixture of two RSs and FPs with different peptide motifs of ECMs increased the efficiency of obtaining neurons differentiated from iPSCs compared to Matrigel. CC consisting of two RSs and FPs with Arg-Gly-Asp-Ser (RGDS) and heparin binding peptide (HBP) is the most effective for the support of NPCs and their neuronal differentiation.


Subject(s)
Fibroins , Induced Pluripotent Stem Cells , Neural Stem Cells , Humans , Fibroins/metabolism , Extracellular Matrix Proteins/metabolism , Neurons , Cell Differentiation , Peptides/pharmacology
3.
Neuropeptides ; 96: 102287, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36280440

ABSTRACT

The mechanisms of the neuroprotective action of the hexapeptides HLDF-6 encoded by the amino acid sequence 41-46 of Human Leukemia Differentiation Factor and its homoserine derivative HLDF-6H were studied in an experimental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of Parkinson's disease (PD). C57Bl/6 mice received two intraperitoneal injections of 18 mg/kg MPTP-HCl, with an interval of 2 hours. MPTP-induced motor dysfunction was assessed using horizontal grid test. Our data show that chronic intranasal administration of peptides (3 weeks, 300 µg/kg/day) restored normal levels of dopamine and improved its turnover rates in the striatum. Furthermore, peptide administration increased serum estradiol levels and led to a significant improvement in motor functions in MPTP-treated mice. Additionally, peptide treatment increased the levels of mRNA encoding neurotrophin BDNF, but normalized the levels of mRNA encoding the inflammatory mediators TGFß1, IL1ß and IFNγ in the brain. Collectively, our behavioral and biochemical studies demonstrate that HLDF-6 peptides have a therapeutic potential for treating PD. We propose that HLDF-6 peptides may exert their neuroprotective mechanism, at least in part, by normalizing estradiol levels and modulating the expression of key factors involved in neurotrophic support and neuroinflammation.


Subject(s)
Neuroprotective Agents , Parkinson Disease , Mice , Animals , Humans , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Parkinson Disease/drug therapy , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/therapeutic use , Mice, Inbred C57BL , Peptides/pharmacology , Peptides/therapeutic use , Estradiol , Models, Theoretical , RNA, Messenger , Disease Models, Animal
4.
Int J Mol Sci ; 23(9)2022 Apr 30.
Article in English | MEDLINE | ID: mdl-35563389

ABSTRACT

Neurodegenerative diseases and depression are multifactorial disorders with a complex and poorly understood physiopathology. Astrocytes play a key role in the functioning of neurons in norm and pathology. Stress is an important factor for the development of brain disorders. Here, we review data on the effects of stress on astrocyte function and evidence of the involvement of astrocyte dysfunction in depression and Alzheimer's disease (AD). Stressful life events are an important risk factor for depression; meanwhile, depression is an important risk factor for AD. Clinical data indicate atrophic changes in the same areas of the brain, the hippocampus and prefrontal cortex (PFC), in both pathologies. These brain regions play a key role in regulating the stress response and are most vulnerable to the action of glucocorticoids. PFC astrocytes are critically involved in the development of depression. Stress alters astrocyte function and can result in pyroptotic death of not only neurons, but also astrocytes. BDNF-TrkB system not only plays a key role in depression and in normalizing the stress response, but also appears to be an important factor in the functioning of astrocytes. Astrocytes, being a target for stress and glucocorticoids, are a promising target for the treatment of stress-dependent depression and AD.


Subject(s)
Alzheimer Disease , Astrocytes , Alzheimer Disease/etiology , Alzheimer Disease/pathology , Brain-Derived Neurotrophic Factor/pharmacology , Depression/etiology , Glucocorticoids/pharmacology , Humans
5.
Psychoneuroendocrinology ; 82: 173-186, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28551512

ABSTRACT

Emerging evidence implicates impaired self-regulation of the hypothalamic-pituitary-adrenal (HPA) axis and inflammation as important and closely related components of the pathophysiology of major depression. Antidepressants show anti-inflammatory effects and are suggested to enhance glucocorticoid feedback inhibition of the HPA axis. HPA axis activity is also negatively self-regulated by the adrenocorticotropic hormone (ACTH), a potent anti-inflammatory peptide activating five subtypes of melanocortin receptors (MCRs). There are indications that ACTH-mediated feedback can be activated by noncorticotropic N-terminal ACTH fragments such as a potent anti-inflammatory MC1/3/4/5R agonist α-melanocyte-stimulating hormone (α-MSH), corresponding to ACTH(1-13), and a MC3/5R agonist ACTH(4-10). We investigated whether intraperitoneal administration of rats with these peptides affects anhedonia, which is a core symptom of depression. Inflammation-related anhedonia was induced by a single intraperitoneal administration of a low dose (0.025mg/kg) of lipopolysaccharide (LPS). Stress-related anhedonia was induced by the chronic unpredictable stress (CUS) procedure. The sucrose preference test was used to detect anhedonia. We found that ACTH(4-10) pretreatment decreased LPS-induced increase in serum corticosterone and tumor necrosis factor (TNF)-α, and a MC3/4R antagonist SHU9119 blocked this effect. Both α-MSH and ACTH(4-10) alleviated LPS-induced anhedonia. In the CUS model, these peptides reduced anhedonia and normalized body weight gain. The data indicate that systemic α-MSH and ACTH(4-10) produce an antidepressant-like effect on anhedonia induced by stress or inflammation, the stimuli that trigger the release of ACTH and α-MSH into the bloodstream. The results suggest a counterbalancing role of circulating melanocortins in depression and point to a new approach for antidepressant treatment.


Subject(s)
Adrenocorticotropic Hormone/pharmacology , Anhedonia/drug effects , Adrenocorticotropic Hormone/metabolism , Anhedonia/physiology , Animals , Corticosterone/blood , Depressive Disorder, Major/immunology , Depressive Disorder, Major/metabolism , Hypothalamo-Hypophyseal System/metabolism , Inflammation/immunology , Male , Peptide Fragments/pharmacology , Peptides/therapeutic use , Pituitary-Adrenal System/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Corticotropin/metabolism , Receptors, Melanocortin/blood , Receptors, Melanocortin/metabolism , Stress, Psychological/metabolism , alpha-MSH/metabolism , alpha-MSH/pharmacology
6.
Restor Neurol Neurosci ; 26(1): 35-43, 2008.
Article in English | MEDLINE | ID: mdl-18431004

ABSTRACT

PURPOSE: It is well established that cholinergic neurons of the basal forebrain degenerate in Alzheimer's dementia. Although recent studies were concentrated on screening molecules that might reduce the concomitant cell loss, little is known about therapeutically promising molecules. We studied the effect of Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a behaviorally active adrenocorticotropic hormone (4-10) analogue, on survival of cholinergic basal forebrain neurons in vitro. Semax is known to stimulate learning and memory and can be successfully used for treatment of ischemic stroke. METHODS: Primary cultures of neuronal and glial cells from basal forebrain of rats were used in all experiments. The stability of Semax in cell cultures was tested by HPLC analysis. Cell survival in neuronal cultures was quantitated using immocytochemical and cytochemical analyses as well as detection of choline acetyltransferase activity. RESULTS: We have shown that Semax may approximately 1.5-1.7 fold increase survival of cholinergic basal forebrain neurons in vitro. Moreover, Semax (100 nM) stimulated activity of choline acetyltransferase in dissociated basal forebrain tissue cultures. However, the numbers of GABA-ergic neurons, total neuron specific enolase neurons were not affected. In concentration from 1 nM to 10 microM, Semax did not affect proliferation of glial cells in primary cultures. CONCLUSION: Implications of these findings with respect to Alzheimer's disease remain to be clarified.


Subject(s)
Adrenocorticotropic Hormone/analogs & derivatives , Choline O-Acetyltransferase/metabolism , Neurons/drug effects , Neuroprotective Agents/pharmacology , Peptide Fragments/pharmacology , Prosencephalon/cytology , Adrenocorticotropic Hormone/pharmacology , Animals , Animals, Newborn , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Gene Expression Regulation/drug effects , Glial Fibrillary Acidic Protein/metabolism , Neuroglia/drug effects , Phosphopyruvate Hydratase/metabolism , Rats , Time Factors , gamma-Aminobutyric Acid/metabolism
7.
Brain Res ; 1117(1): 54-60, 2006 Oct 30.
Article in English | MEDLINE | ID: mdl-16996037

ABSTRACT

The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analog of the adrenocorticotropin fragment (4-10) which after intranasal application has profound effects on learning and exerts marked neuroprotective activities. Here, we found that a single application of Semax (50 microg/kg body weight) results in a maximal 1.4-fold increase of BDNF protein levels accompanying with 1.6-fold increase of trkB tyrosine phosporylation levels, and a 3-fold and a 2-fold increase of exon III BDNF and trkB mRNA levels, respectively, in the rat hippocampus. Semax-treated animals showed a distinct increase in the number of conditioned avoidance reactions. We suggest that Semax affects cognitive brain functions by modulating the expression and the activation of the hippocampal BDNF/trkB system.


Subject(s)
Adrenocorticotropic Hormone/analogs & derivatives , Brain-Derived Neurotrophic Factor/drug effects , Hippocampus/drug effects , Peptide Fragments/pharmacology , Receptor, trkB/drug effects , Administration, Intranasal , Adrenocorticotropic Hormone/chemistry , Adrenocorticotropic Hormone/pharmacology , Animals , Avoidance Learning/drug effects , Avoidance Learning/physiology , Body Weight/drug effects , Body Weight/physiology , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Cognition/drug effects , Cognition/physiology , Conditioning, Psychological/drug effects , Conditioning, Psychological/physiology , Dose-Response Relationship, Drug , Exons/drug effects , Exons/genetics , Hippocampus/metabolism , Nootropic Agents/pharmacology , Peptide Fragments/chemistry , RNA, Messenger/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Reaction Time/drug effects , Reaction Time/physiology , Receptor, trkB/genetics , Receptor, trkB/metabolism , Up-Regulation/drug effects , Up-Regulation/physiology
8.
J Neurochem ; 97 Suppl 1: 82-6, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16635254

ABSTRACT

The heptapeptide Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is an analogue of the N-terminal fragment (4-10) of adrenocorticotropic hormone which, after intranasal application, has profound effects on learning and memory formation in rodents and humans, and also exerts marked neuroprotective effects. A clue to the molecular mechanism underlying this neurotropic action was recently given by the observation that Semax stimulates the synthesis of brain-derived neurotrophic factor (BDNF), a potent modulator of synaptic plasticity, in astrocytes cultured from rat basal forebrain. In the present study, we investigated whether Semax affects BDNF levels in rat basal forebrain upon intranasal application of the peptide. In addition, we examined whether cell membranes isolated from this brain region contained binding sites for Semax. The binding of tritium-labelled Semax was found to be time dependent, specific and reversible. Specific Semax binding required calcium ions and was characterized by a mean+/-SEM dissociation constant (KD) of 2.4+/-1.0 nm and a BMAX value of 33.5+/-7.9 fmol/mg protein. Sandwich immunoenzymatic analysis revealed that Semax applied intranasally at 50 and 250 microg/kg bodyweight resulted in a rapid increase in BDNF levels after 3 h in the basal forebrain, but not in the cerebellum. These results point to the presence of specific binding sites for Semax in the rat basal forebrain. In addition, these findings indicate that the cognitive effects exerted by Semax might be associated, at least in part, with increased BDNF protein levels in this brain region.


Subject(s)
Adrenocorticotropic Hormone/analogs & derivatives , Brain-Derived Neurotrophic Factor/metabolism , Neuroprotective Agents , Peptide Fragments/metabolism , Peptide Fragments/pharmacology , Prosencephalon/drug effects , Prosencephalon/metabolism , Administration, Intranasal , Adrenocorticotropic Hormone/metabolism , Adrenocorticotropic Hormone/pharmacology , Animals , Brain-Derived Neurotrophic Factor/genetics , Calcium/pharmacology , Cell Membrane/metabolism , Cells, Cultured , Immunoenzyme Techniques , Male , Manganese/pharmacology , Neuroprotective Agents/metabolism , Neuroprotective Agents/pharmacology , RNA, Messenger/analysis , Rats , Rats, Wistar , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...